|
Brain Ischemia
|
0.200 |
Biomarker
|
disease |
RGD |
Caspase mRNA expression in a rat model of focal cerebral ischemia.
|
11311984 |
2001 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats.
|
15662549 |
2004 |
|
Endometritis
|
0.200 |
Therapeutic
|
disease |
RGD |
Selenium Plays a Protective Role in Staphylococcus aureus-Induced Endometritis in the Uterine Tissue of Rats.
|
26920733 |
2016 |
|
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Ischemic preconditioning attenuates ischemia-reperfusion-induced mucosal apoptosis by inhibiting the mitochondria-dependent pathway in rat small intestine.
|
15010362 |
2004 |
|
Status Epilepticus
|
0.200 |
Biomarker
|
disease |
RGD |
Our data demonstrated that the SE-induced increase in the expression of cleaved caspase 6 and its intraneuronal localization were dependent on the time delay from SE induction.
|
15749343 |
2005 |
|
Sepsis
|
0.200 |
Biomarker
|
disease |
RGD |
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.
|
11086028 |
2000 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
RGD |
Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.
|
11406539 |
2001 |
|
Infarction, Middle Cerebral Artery
|
0.200 |
Biomarker
|
disease |
RGD |
4'-O-β-D-Glucosyl-5-O-Methylvisamminol, A Natural Histone H3 Phosphorylation Epigenetic Suppressor, Exerts a Neuroprotective Effect Through PI3K/Akt Signaling Pathway on Focal Cerebral Ischemia in Rats.
|
26868427 |
2016 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
Collectively, these results suggest a role for caspase-6 and N-terminal truncation of tau during neurofibrillary tangle evolution and the progression of Alzheimer's disease.
|
15356202 |
2004 |
|
Stomach Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas.
|
16948818 |
2006 |
|
Stomach Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Loss of caspase-2, -6 and -7 expression in gastric cancers.
|
15511269 |
2004 |
|
Colonic Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53.
|
18497562 |
2008 |
|
Colorectal Neoplasms
|
0.010 |
GeneticVariation
|
group |
LHGDN |
Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas.
|
16948818 |
2006 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, numerous findings implicate Caspase-6 (Casp6) in neurodegenerative diseases, including Alzheimer disease (AD) and Huntington disease (HD), highlighting the need for a deeper understanding of Casp6 biology and its role in brain development.
|
22262731 |
2012 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The excess neuronal activity of Caspase-6 is associated with Alzheimer disease neuropathology and age-dependent cognitive impairment.
|
30940883 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Caspase-6 (casp6) in particular has been shown to play a key role in the pathogenesis of stroke, Huntington disease, and Alzheimer disease.
|
29193273 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taking advantage of reconstitution experiments with SMSr produced in a cell-free expression system, specific caspase-inhibitors and gene silencing approaches, we show that SMSr is a novel and specific substrate of caspase-6, a non-conventional effector caspase implicated in Huntington's and Alzheimer's diseases.
|
28659495 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thioredoxin system as a gatekeeper in caspase-6 activation and nuclear lamina integrity: Implications for Alzheimer's disease.
|
30769159 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that CSF TauΔCasp6 levels hold promise as a novel early biomarker of AD.
|
23965742 |
2013 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The activation of the aspartate-specific cysteinyl protease, Caspase-6, is proposed as an early pathogenic event of Alzheimer disease (AD) and Huntington's disease.
|
28241839 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that full Casp6 activity may not be essential for healthy humans and support the use of Casp6 inhibitors against Casp6-dependent neurodegeneration in age-dependent cognitive impairment and AD.
|
29535332 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that Caspase-6-mediated damage is reversible months after the onset of cognitive deficits and suggest that methylene blue could benefit Alzheimer disease patients by reversing Caspase-6-mediated cognitive decline.
|
31843022 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Caspase-6 has recently been implicated in neurodegenerative conditions including Huntington's and Alzheimer's diseases.
|
22483120 |
2012 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because sporadic and familial AD cases have similar pathological features, these results support a fundamental role of Casp-6 in the pathophysiology of both familial and sporadic AD.
|
19915487 |
2009 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Caspase-6 (CASP6) has emerged as an important player in Huntington disease (HD), Alzheimer disease (AD) and cerebral ischemia, where it is activated early in the disease process.
|
26908611 |
2016 |